Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study

Abstract

Background: The concurrent chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This randomized, phase III trial aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of gemcitabine, cisplatin, XRT. Materials and Methods: Stage IIB-IIIB, 18-70 years of age, KPS score ≥70, were randomized to control group and study group. Control group received cisplatin 40 mg/m 2 weekly with concurrent XRT, followed by brachytherapy and study group received gemcitabine 125 mg/m 2 weekly top of the same control group treatment. The primary end point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS and OS. Fifty patients were randomized between two arms. Results: The complete response in study and control arm was 96% and 88% respectively. Toxicities was significantly high in the study group compared to control group [leucopenia (P=0.015), skin reaction (P=0.03) and bleeding (P=0.019)]. Local recurrence rate: 8% in study arm, none in control arm. The distant failure prevailed in control arm (20% vs. 8%). On a median follow up of 21 months in control arm, the DFS was 73% whereas 83% in study arm in 16 months (P=0.69). OS in the study arm was 100% and 84.5% in the control arm (P=0.14). Conclusions: If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer.

Keywords

Cisplatine - gemcitabine - radiotherapy in CA cervix

Publication History

Article published online:
06 August 2021

• References

• 1 Parkin DM, Pisani P, Ferlay J. Estimates of the world wide incidence of 18 major cancers in 1985. Int J Cancer 1993;54:594-606.
• 2 Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin 1999;49:33-64.
• 3 Chaudhury K. Indian trends in cervical cancers: Recent developments of cancer of uterine cervix 6 th annual symposium. New Delhi: Ranbaxy Scientific Foundation; 1999. p. 13-7.
• 4 Munoz N, Bosch FX. Epidemiology of cervical cancer. In: Munoz N, Bosch FX, Jensen OM editors. Human Papilloma Virus and cervical cancer IARC Scientific publication No. 94, Lyon, France: International Agency to Research on Cancer; 1989. p. 9-39.
• 5 Dutta PK, Major Upadhyay A, Dutta M, Urmil AC, Thergaonkar MP, Ganguly SS. A case control study of cancer cervix patients attending command hospital, Pune. Indian J Cancer 1990;27:101-8.
• 6 Kessler II. Cervical cancer as a veneral disease. Cancer Res 1976;36:783-91.
• 7 Candelaria M, Cetina L, de la Garza J, Duenas-Gonzalez A. Clinical implication of gemcitabine in the treatment of cervical cancer. Eur J Cancer 2007;2:37-43.
• 8 Wallner KE, Li GC. Effect of Cisplatin resistance on cellular radiation response. Int J Radiat Oncol Biol Phys 1987;13:587-91.
• 9 McGinn CJ, Smith DC, Szarka CJ. Phase I study of gemcitabine in locally advanced cervical cancer with radiation therapy. Proc Am Soc Clin Oncol 1998;17:264.
• 10 Hernandez P, Olivera P, Duenas-Gonzalez A, Pérez-Pastenes MA, Zárate A, Maldonado V, et al. Gemcitabine activity in cervical cancer cell lines Mexico. Cancer Chemother Pharmacol 2001;48:488-92.
• 11 Savarese A, Cognetti F. New drugs in recurrent and metastatic cervical cancer. Crit Rev Oncol Hematol 2003;48:323-7.
• 12 McCormack M, Thomas H. Phase IB study of gemcitabine and concurrent radiotherapy in carcinoma of the cervix. Ann Oncology 2000;11:88-9.
• 13 Chumworathayi B, Yuenyao P, Tangvorapongchai V. Weekly gemcitabine dosing on locally advanced cancer cervix of Thai women 25. Japanese journal of radiology 2007;9:474-9.
• 14 Zarba JJ, Jaremtchuk AV, Gonzalez Jazey P, Keropian M, Castagnino R, Mina C, et al. A phase I-II study of weekly cisplatin and Gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol 2003;14:1285-90.
• 15 Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3 rd , et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
• 16 Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
• 17 Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
• 18 Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes, Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
• 19 Wong LC, Ngan HY, Cheung AN, Cheng DK, Ng TY, Choy DT. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999;17:2055-60.
• 20 Pearcey R, Brundage M, Jeffrey J. A clinical trial comparing concurrent cisplatin and radiation therapy vs radiation alone for locally advance squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 2000;19:378 (abstract).
• 21 Kapp KS, Stuecklschweiger GF, Kapp DS, Poschauko J,Pickel H, Hackl A. Carcinoma of the cervix: Analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy. Radiother Oncol. 1997; 42 (2): 143-53.
• 22 Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3 rd , et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
• 23 Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
• 24 Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
• 25 Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes, a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
• 26 Peters WA 3 rd , Lui PY, Barrett RJ 2 nd , Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
• 27 Duenas-Gonzalez A, Cetina-Pervez L, Lopez-Graniel C, Gonzalez-Enciso A, Gómez-Gonzalez E, Rivera-Rubi L, et al. Pathologic response and toxicity assessment of chemotherapy with cisplatin versus cisplatin plus Gemcitabine in cervical cancer, A Randomized phase II study. Int J Radiat Oncol Biol Phys 2005;61:817-23.
• 28 Umanzor J, Aguiluz M, Pineda C, Andrade S, Erazo M, Flores C, et al. Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trial. Gynecol Oncol 2005;100:70-5.